Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
156.23B
Market cap156.23B
Price-Earnings ratio
36.81
Price-Earnings ratio36.81
Dividend yield
6.19%
Dividend yield6.19%
Average volume
30.92M
Average volume30.92M
High today
$27.79
High today$27.79
Low today
$27.12
Low today$27.12
Open price
$27.65
Open price$27.65
Volume
32.35M
Volume32.35M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $27.45. The company's market cap stands at 156.23B, with a P/E ratio of 36.81 and a dividend yield of 6.19%.

During the trading session on 2026-10-05, Pfizer(PFE) shares reached a daily high of $27.79 and a low of $27.12. At a current price of $27.45, the stock is +1.2% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 32.35M, compared to an average daily volume of 30.92M.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

PFE News

The Motley Fool 50m
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now

Pfizer (PFE -1.35%) has been a reliable healthcare company to invest in for decades, also providing shareholders with some terrific dividend income along the wa...

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
Benzinga 2h
Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims

A legal filing in Florida accuses pharmaceutical giant Pfizer Inc. (NYSE:PFE) and Chairman and CEO Albert Bourla of deceiving consumers by concealing critical s...

Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
24/7 Wall St. 2h
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Investing Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading...

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Analyst ratings

61%

of 28 ratings
Buy
32.1%
Hold
60.7%
Sell
7.1%

More PFE News

Investor's Business Daily 7h
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Technology Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study Licensing Vaxcyte (PCVX) stock catapulted to a nearly two-year high Mond...

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
The Motley Fool 8h
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Is it better to pay a premium for explosive growth or hunt for value in a steady giant? This is the central question for investors choosing between Eli Lilly (L...

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
24/7 Wall St. 9h
Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

Investing Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside Ten consecutive earnings beats and a shrinking COVID hangover have Wall S...

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
The Motley Fool 12h
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.

"It takes money to make money." You've probably heard that statement many times. And it's usually true. However, some assets allow you to make more money with l...

Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.
The Motley Fool 23h
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?

Dividend investors are usually drawn like moths to high-yield stocks. That makes total sense, but a string of recent dividend cuts announced by companies like C...

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
24/7 Wall St. 1d
Pay Me While I Wait: 3 Turnaround Stocks That Keep Paying Investors Through the Rebuild

Investing Pay Me While I Wait: 3 Turnaround Stocks That Keep Paying Investors Through the Rebuild Three struggling companies keep sending dividend checks while...

Pay Me While I Wait: 3 Turnaround Stocks That Keep Paying Investors Through the Rebuild
The Motley Fool 1d
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Have you ever heard the expression "if it sounds too good to be true, it probably is"? It's an admittedly fair assessment of many offers and prospects, includin...

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.